|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
Here's a thumbnail sketch:
SIBIA Neurosciences, Inc. is engaged in the discovery and development of novel, small molecule therapeutics for nervous system disorders based on the Company's unique approach to characterizing the molecular processes involved in such disorders. SIBIA is focusing its efforts on discovering and developing compounds for the treatment of Parkinson's disease, Alzheimer's disease, stroke, depression, head trauma, epilepsy, chronic pain, schizophrenia and other neurological, psychiatric and neurodegenerative disorders. The Company currently has collaborations with Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company and Meiji Seika Kaisha, Ltd.
Anyone have more information on this company?
|© 2023 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|